Search research articles
Contact Us
Filters
Showing results (61-70 of 71) with videos related to
Page
of 8
Sort By:
Scientific Reports
|
July 6, 2022
REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats
Jack Henningfield, David Gauvin, Francesco Bifari, et al.
Molecular Psychiatry
|
May 28, 2024
Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone'
Marco Pappagallo, Thomas R Kosten, Charles W Gorodetzky, et al.
The Journal of Clinical Psychiatry
|
October 8, 2025
Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis: An Exploratory Post Hoc Analysis From a Phase 3 Randomized Controlled Trial
Clotilde Guidetti, George I Papakostas, Luca Pani, et al.
International Journal of Molecular Sciences
|
October 27, 2022
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling
Stephen M Stahl, Sara De Martin, Andrea Mattarei, et al.
Pharmaceuticals (Basel, Switzerland)
|
August 26, 2022
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
Ezio Bettini, Stephen M Stahl, Sara De Martin, et al.
European Archives of Psychiatry and Clinical Neuroscience
|
March 8, 2023
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
Maurizio Fava, Stephen M Stahl, Sara De Martin, et al.
International Clinical Psychopharmacology
|
February 27, 2026
Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants
Clotilde Guidetti, George I Papakostas, Steven Stahl, et al.
The Journal of Clinical Psychiatry
|
February 25, 2025
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study
Maurizio Fava, Luca Pani, Sara De Martin, et al.
The American Journal of Psychiatry
|
December 22, 2021
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial
Maurizio Fava, Stephen Stahl, Luca Pani, et al.
The Journal of Clinical Psychiatry
|
June 25, 2024
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial
Maurizio Fava, Stephen M Stahl, Luca Pani, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 71) with videos related to
Sort By:
Page
of 8
Scientific Reports
|
July 6, 2022
REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats
Jack Henningfield, David Gauvin, Francesco Bifari, et al.
Molecular Psychiatry
|
May 28, 2024
Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone'
Marco Pappagallo, Thomas R Kosten, Charles W Gorodetzky, et al.
The Journal of Clinical Psychiatry
|
October 8, 2025
Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis: An Exploratory Post Hoc Analysis From a Phase 3 Randomized Controlled Trial
Clotilde Guidetti, George I Papakostas, Luca Pani, et al.
International Journal of Molecular Sciences
|
October 27, 2022
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling
Stephen M Stahl, Sara De Martin, Andrea Mattarei, et al.
Pharmaceuticals (Basel, Switzerland)
|
August 26, 2022
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
Ezio Bettini, Stephen M Stahl, Sara De Martin, et al.
European Archives of Psychiatry and Clinical Neuroscience
|
March 8, 2023
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
Maurizio Fava, Stephen M Stahl, Sara De Martin, et al.
International Clinical Psychopharmacology
|
February 27, 2026
Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants
Clotilde Guidetti, George I Papakostas, Steven Stahl, et al.
The Journal of Clinical Psychiatry
|
February 25, 2025
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study
Maurizio Fava, Luca Pani, Sara De Martin, et al.
The American Journal of Psychiatry
|
December 22, 2021
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial
Maurizio Fava, Stephen Stahl, Luca Pani, et al.
The Journal of Clinical Psychiatry
|
June 25, 2024
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial
Maurizio Fava, Stephen M Stahl, Luca Pani, et al.
Page
of 8